New Parkinson's drug candidate PDM608 begins first human safety tests
NCT ID NCT05950906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the safety and tolerability of a new drug called PDM608 in 64 healthy adults. The goal was to see if the drug is safe enough to study further in people with Parkinson's disease. Participants received either PDM608 or a placebo, and researchers monitored for side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PDM608
- What this could lead to
- If successful, this could lead to a new treatment option for Parkinson's disease.
- What could go wrong
- This is a very early Phase 1 trial in healthy volunteers, not people with Parkinson's. It only tests safety and dosing, not whether the drug works for the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Quotient Sciences-Miami, Inc
Miami, Florida, 33126, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Planning ahead: could a simple program transform Parkinson's care?
- Sound waves vs. Parkinson's: can ultrasound calm tremors and stiffness?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Could a brain disease change behavior years before diagnosis?